Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial (Q42943536)
Jump to navigation
Jump to search
scientific article published on 6 August 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial |
scientific article published on 6 August 2010 |
Statements
1 reference
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial (English)
1 reference
Paul Y Kwo
1 reference
Eric J Lawitz
1 reference
Jonathan McCone
1 reference
Eugene R Schiff
1 reference
John M Vierling
1 reference
David Pound
1 reference
Mitchell N Davis
1 reference
Joseph S Galati
1 reference
Stuart C Gordon
1 reference
Natarajan Ravendhran
1 reference
Lorenzo Rossaro
1 reference
Frank H Anderson
1 reference
Ira M Jacobson
1 reference
Raymond Rubin
1 reference
Kenneth Koury
1 reference
Lisa D Pedicone
1 reference
Clifford A Brass
1 reference
Eirum Chaudhri
1 reference
Janice K Albrecht
1 reference
SPRINT-1 investigators
1 reference
6 August 2010
1 reference
1 reference
Identifiers
1 reference